Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 1.00 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.97 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | S100B | P04271 | 2/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14487035 | 0.98 | IP6K1 (1.00) | MAP4K4IP6K1IP6K3PRKDCMAPT | |
| SCHEMBL12733339 | 0.88 | MAP4K4 (0.78) | MAP4K4IP6K1PRKDCMAPTS100B | |
| SCHEMBL10968370 | 0.85 | IP6K1 (0.76) | MAP4K4IP6K1MAPTMEN1ALDH1A1 | |
| SCHEMBL30775562 | 0.85 | IP6K1 (0.76) | MAP4K4IP6K1MAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30575860 | 0.84 | IP6K1 (0.74) | MAP4K4IP6K1MAPTMEN1ALDH1A1 | |
| SCHEMBL30478684 | 0.82 | IP6K1 (0.71) | MAP4K4IP6K1IP6K3PRKDC | |
| SCHEMBL8871494 | 0.81 | MAP4K4 (0.68) | MAP4K4IP6K1IP6K3PRKDCMAPT | |
| SCHEMBL8976481 | 0.79 | IP6K1 (0.68) | MAP4K4IP6K1IP6K3PRKDCMAPT | |
| SCHEMBL30210340 | 0.78 | MAP4K4 (0.64) | MAP4K4IP6K1IP6K3PRKDCMAPT | |
| SCHEMBL14536922 | 0.77 | IP6K1 (0.63) | MAP4K4IP6K1IP6K3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | disclosed |
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | PFIZER INC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101618-A1 | Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer | ERBB2, ERBB3, EGFR | MAP4K4 138/4885IP6K1 1444/4885IP6K3 1378/4885 |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885IP6K1 2927/4885IP6K3 2210/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | MAP4K4 164/4885IP6K1 1375/4885IP6K3 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.